Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mannitol in cardiopulmonary bypass priming during CABG
IRCT20221129056660N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Dec 2022
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Bronchitol in coronary arteriosclerosis (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Cardiac enzymes, Serum creatinine and 7 more. Started Dec 2022; status: completed.
02
Drugs
Bronchitol
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20221129056660N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221129056660N1.